Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium

Britton Trabert*, Elizabeth M. Poole, Emily White, Kala Visvanathan, Hans-Olov Adami, Garnet L. Anderson, Theodore M. Brasky, Louise A. Brinton, Renee T. Fortner, Mia Gaudet, Patricia Hartge, Judith Hoffman-Bolton, Michael Jones, James V. Lacey, Susanna C. Larsson, Gerardo G. Mackenzie, Leo J. Schouten, Dale P. Sandler, Katie O'Brien, Alpa V. PatelUlrike Peters, Anna Prizment, Kim Robien, V. Wendy Setiawan, Anthony Swerdlow, Piet A. van den Brandt, Elisabete Weiderpass, Lynne R. Wilkens, Alicja Wolk, Nicolas Wentzensen, Shelley S. Tworoger, Ovarian Cancer Cohort Consortium OC3

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Web of Science)
Original languageEnglish
Pages (from-to)137-145
Number of pages9
JournalJournal of the National Cancer Institute
Volume111
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • NONSTEROIDAL ANTIINFLAMMATORY DRUGS
  • LIFETIME OVULATORY CYCLES
  • LOW-DOSE ASPIRIN
  • BREAST-CANCER
  • PRIMARY PREVENTION
  • WOMENS HEALTH
  • ACETAMINOPHEN
  • INFLAMMATION
  • ASSOCIATION
  • DISEASE

Cite this